Lycera Secures $29,892,748 Series B Financing

  • Feed Type
  • Date
    6/22/2015
  • Company Name
    Lycera
  • Mailing Address
    2800 Plymouth Rd. Ann Arbor, MI 48109 USA
  • Company Description
    Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.
  • Website
    http://www.lycera.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $29,892,748
  • Transaction Round
    Series B
  • Proceeds Purposes
    Amount includes Conversion of Convertible Promissory Notes for Series B Preferred Stock and the purchase of Series B-1 Preferred Stock for cash. Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor

Trending on Xconomy